世界のα1アンチトリプシン欠乏症増強療法市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12039 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、α1アンチトリプシン欠乏症増強療法のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。α1アンチトリプシン欠乏症増強療法の種類別市場規模（グラシア、アララストNP、プロラスチンC、その他）、用途別市場規模（病院、専門クリニック）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・α1アンチトリプシン欠乏症増強療法の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Grifols、CSL、Baxter、Kamada、Takeda、Abeona ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：グラシア、アララストNP、プロラスチンC、その他 ・用途別分析2016年-2026年：病院、専門クリニック ・α1アンチトリプシン欠乏症増強療法の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・α1アンチトリプシン欠乏症増強療法のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・α1アンチトリプシン欠乏症増強療法のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・α1アンチトリプシン欠乏症増強療法の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・α1アンチトリプシン欠乏症増強療法の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Alpha-1 Antitrypsin Deficiency Augmentation Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Alpha-1 Antitrypsin Deficiency Augmentation Therapy market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Glassia
Aralast NP
Prolastin C
Others

Market segment by Application, can be divided into
Hospitals
Specialty Clinics

Market segment by players, this report covers
Grifols
CSL
Baxter
Kamada
Takeda
Abeona

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Alpha-1 Antitrypsin Deficiency Augmentation Therapy
1.2 Classification of Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Type
1.2.1 Overview: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type in 2020
1.2.3 Glassia
1.2.4 Aralast NP
1.2.5 Prolastin C
1.2.6 Others
1.3 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market by Application
1.3.1 Overview: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size & Forecast
1.5 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast by Region
1.5.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region, (2016-2021)
1.5.3 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Prospect (2016-2026)
1.5.4 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Prospect (2016-2026)
1.5.6 South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Drivers
1.6.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Restraints
1.6.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Trends Analysis
2 Company Profiles
2.1 Grifols
2.1.1 Grifols Details
2.1.2 Grifols Major Business
2.1.3 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product and Solutions
2.1.4 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Grifols Recent Developments and Future Plans
2.2 CSL
2.2.1 CSL Details
2.2.2 CSL Major Business
2.2.3 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product and Solutions
2.2.4 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 CSL Recent Developments and Future Plans
2.3 Baxter
2.3.1 Baxter Details
2.3.2 Baxter Major Business
2.3.3 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product and Solutions
2.3.4 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Baxter Recent Developments and Future Plans
2.4 Kamada
2.4.1 Kamada Details
2.4.2 Kamada Major Business
2.4.3 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product and Solutions
2.4.4 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Kamada Recent Developments and Future Plans
2.5 Takeda
2.5.1 Takeda Details
2.5.2 Takeda Major Business
2.5.3 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product and Solutions
2.5.4 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Takeda Recent Developments and Future Plans
2.6 Abeona
2.6.1 Abeona Details
2.6.2 Abeona Major Business
2.6.3 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product and Solutions
2.6.4 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Abeona Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players Market Share
3.2.2 Top 10 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players Market Share
3.2.3 Market Competition Trend
3.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Market Share by Type (2016-2021)
4.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Application (2016-2021)
5.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2016-2026)
6.2 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2016-2026)
6.3 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country
6.3.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country (2016-2026)
6.3.2 United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
6.3.3 Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
6.3.4 Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2016-2026)
7.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2016-2026)
7.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country
7.3.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country (2016-2026)
7.3.2 Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
7.3.3 France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
7.3.5 Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
7.3.6 Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2016-2026)
8.2 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2016-2026)
8.3 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region
8.3.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Region (2016-2026)
8.3.2 China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
8.3.3 Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
8.3.4 South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
8.3.5 India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
8.3.7 Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2016-2026)
9.2 South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2016-2026)
9.3 South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country
9.3.1 South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country (2016-2026)
9.3.2 Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
9.3.3 Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2016-2026)
10.2 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2016-2026)
10.3 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country
10.3.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country (2016-2026)
10.3.2 Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
10.3.4 UAE Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million) by Region (2016-2021)
Table 5. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Region (2021-2026)
Table 6. Grifols Corporate Information, Head Office, and Major Competitors
Table 7. Grifols Major Business
Table 8. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product and Solutions
Table 9. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. CSL Corporate Information, Head Office, and Major Competitors
Table 11. CSL Major Business
Table 12. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product and Solutions
Table 13. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Baxter Corporate Information, Head Office, and Major Competitors
Table 15. Baxter Major Business
Table 16. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product and Solutions
Table 17. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Kamada Corporate Information, Head Office, and Major Competitors
Table 19. Kamada Major Business
Table 20. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product and Solutions
Table 21. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Takeda Corporate Information, Head Office, and Major Competitors
Table 23. Takeda Major Business
Table 24. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product and Solutions
Table 25. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Abeona Corporate Information, Head Office, and Major Competitors
Table 27. Abeona Major Business
Table 28. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product and Solutions
Table 29. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million) by Players (2019-2021)
Table 31. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Share by Players (2019-2021)
Table 32. Breakdown of Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 33. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players Head Office, Products and Services Provided
Table 34. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Mergers & Acquisitions in the Past Five Years
Table 35. Alpha-1 Antitrypsin Deficiency Augmentation Therapy New Entrants and Expansion Plans
Table 36. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million) by Type (2016-2021)
Table 37. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Share by Type (2016-2021)
Table 38. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Forecast by Type (2021-2026)
Table 39. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2016-2021)
Table 40. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Forecast by Application (2021-2026)
Table 41. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2016-2021) & (USD Million)
Table 42. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2021-2026) & (USD Million)
Table 43. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2016-2021) & (USD Million)
Table 44. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2021-2026) & (USD Million)
Table 45. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country (2016-2021) & (USD Million)
Table 46. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country (2021-2026) & (USD Million)
Table 47. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2016-2021) & (USD Million)
Table 48. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2021-2026) & (USD Million)
Table 49. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2016-2021) & (USD Million)
Table 50. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2021-2026) & (USD Million)
Table 51. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country (2016-2021) & (USD Million)
Table 52. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country (2021-2026) & (USD Million)
Table 53. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2016-2021) & (USD Million)
Table 54. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2021-2026) & (USD Million)
Table 55. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2016-2021) & (USD Million)
Table 56. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2021-2026) & (USD Million)
Table 57. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Region (2016-2021) & (USD Million)
Table 58. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Region (2021-2026) & (USD Million)
Table 59. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2016-2021) & (USD Million)
Table 60. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2021-2026) & (USD Million)
Table 61. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2016-2021) & (USD Million)
Table 62. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2021-2026) & (USD Million)
Table 63. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country (2016-2021) & (USD Million)
Table 64. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country (2021-2026) & (USD Million)
Table 65. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2016-2021) & (USD Million)
Table 66. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Type (2021-2026) & (USD Million)
Table 67. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2016-2021) & (USD Million)
Table 68. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Application (2021-2026) & (USD Million)
Table 69. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country (2016-2021) & (USD Million)
Table 70. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Picture
Figure 2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type in 2020
Figure 3. Glassia
Figure 4. Aralast NP
Figure 5. Prolastin C
Figure 6. Others
Figure 7. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Application in 2020
Figure 8. Hospitals Picture
Figure 9. Specialty Clinics Picture
Figure 10. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Region (2016-2026)
Figure 13. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Region in 2020
Figure 14. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Drivers
Figure 20. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Restraints
Figure 21. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends
Figure 22. Grifols Recent Developments and Future Plans
Figure 23. CSL Recent Developments and Future Plans
Figure 24. Baxter Recent Developments and Future Plans
Figure 25. Kamada Recent Developments and Future Plans
Figure 26. Takeda Recent Developments and Future Plans
Figure 27. Abeona Recent Developments and Future Plans
Figure 28. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Share by Players in 2020
Figure 29. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 30. Global Top 3 Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share in 2020
Figure 31. Global Top 10 Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share in 2020
Figure 32. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 33. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Share by Type in 2020
Figure 34. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share Forecast by Type (2021-2026)
Figure 35. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Share by Application in 2020
Figure 36. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share Forecast by Application (2021-2026)
Figure 37. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Type (2016-2026)
Figure 38. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Application (2016-2026)
Figure 39. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Country (2016-2026)
Figure 40. United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Type (2016-2026)
Figure 44. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Application (2016-2026)
Figure 45. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Country (2016-2026)
Figure 46. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. United Kingdom Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Type (2016-2026)
Figure 52. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Application (2016-2026)
Figure 53. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Region (2016-2026)
Figure 54. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Type (2016-2026)
Figure 61. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Application (2016-2026)
Figure 62. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Country (2016-2026)
Figure 63. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Type (2016-2026)
Figure 66. Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Application (2016-2026)
Figure 67. Middle East and Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Country (2016-2026)
Figure 68. Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. UAE Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Methodology
Figure 72. Research Process and Data Source

---